Injection site and regulatory t cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Bright, Jennifer D ^a   Schultz, Heather N ^a   Byrne, Jennifer A ^b   Bright, Robert K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CD25++ Treg depletion; CD8+ Tregs; MD52 protein; Mouse; TPD52; Vaccin

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 10; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN D52; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PREVENTION; CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SUBCUTANEOUS IMMUNOTHERAPY;

EID: 84886944629     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25049     Document Type: Article

References (47)

1. Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother 2008; 57:799-811; PMID:17962942; http://dx.doi. org/10.1007/s00262-007-0416-y
2. Petrova DT, Asif AR, Armstrong VW, Dimova I, Toshev S, Yaramov N, et al. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin Biochem 2008; 41:1224-36; PMID:18710659; http://dx.doi.org/10.1016/j.clinbiochem. 2008.07.012
3. Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, et al. Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Ca Res 2008; 14:5050-60; http://dx.doi.org/10.1158/1078-0432.CCR-07-4994
4. Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood 2005; 105:2812-20; PMID:15576473; http://dx.doi.org/10.1182/blood- 2004-07-2630
5. Byrne JA, Mattei MG, Basset P. Definition of the D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996; 35:523-32; PMID:8812487; http:// dx.doi.org/10.1006/geno.1996.0393
6. Byrne JA, Tomasetto C, Garnier JM, Rouyer N, Mattei MG, Bellocq JP, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995; 55:2896-903; PMID:7796418
7. Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004; 64:1589-94; PMID:14996714; http://dx.doi.org/10.1158/0008- 5472.CAN-03-3331
8. Byrne JA, Mattei MG, Basset P, Gunning P. Identification and in situ hybridization mapping of a mouse Tpd52l1 (D53) orthologue to chromosome 10A4-B2. Cytogenet Cell Genet 1998; 81:199-201; PMID:9730602; http:// dx.doi.org/10.1159/000015029
9. Byrne JA, Nourse CR, Basset P, Gunning P. Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene 1998; 16:873-81; PMID:9484778; http:// dx.doi.org/10.1038/sj.onc.1201604
10. Nourse CR, Mattei MG, Gunning P, Byrne JA. Cloning of a third member of the D52 gene family indicates alternative coding sequence usage in D52-like transcripts. Biochim Biophys Acta 1998; 1443:155-68; PMID:9838088; http://dx.doi.org/10.1016/S0167- 4781(98)00211-5
11. Cao Q, Chen J, Zhu L, Liu Y, Zhou Z, Sha J, et al. A testis-specific and testis developmentally regulated tumor protein D52 (TPD52)-like protein TPD52L3/hD55 interacts with TPD52 family proteins. Biochem Biophys Res Commun 2006; 344:798-806; PMID:16631610; http://dx.doi.org/10.1016/j. bbrc.2006.03.208
12. Chen SL, Maroulakou IG, Green JE, Romano-Spica V, Modi W, Lautenberger J, et al. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene 1996; 12:741-51; PMID:8632896
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822-6; PMID:11518967; http://dx.doi. org/10.1038/35090585
14. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, et al.Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.Cancer Res 2004; 64:3814-22; PMID:15172988; http://dx.doi.org/10.1158/0008-5472.CAN-03-3881
15. Malek RL, Irby RB, Guo QM, Lee K, Wong S, He M, et al.Identification of Src transformation fingerprint in human colon cancer.Oncogene 2002; 21:7256-65; PMID:12370817; http://dx.doi.org/10.1038/sj.onc.1205900
16. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, et al.Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer 2005; 117:1049-54; PMID:15986428; http://dx.doi.org/10.1002/ijc.21250
17. Byrne JA, Chen Y, Martin La Rotta N, Peters GB.Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.Genes Cancer 2012; 3:87-101; PMID:23050042; http://dx.doi.org/10.1177/1947601912456287
18. Todaro GJ, Green H.Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines.J Cell Biol 1963; 17:299-313; PMID:13985244; http://dx.doi.org/10.1083/jcb.17.2.299
19. Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.Cancer Immunol Immunother 2009; 58:1337-49; PMID:19169682; http://dx.doi.org/10.1007/s00262-009-0659-x
20. Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, et al.Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.Vaccine 2009; 27:1825-33; PMID:19201387; http://dx.doi.org/10.1016/j.vaccine.2009.01.089
21. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, et al.Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.Mol Cancer Res 2007; 5:133-44; PMID:17314271; http://dx.doi.org/10.1158/1541-7786.MCR-06-0245
22. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
23. Schreiber TH, Raez L, Rosenblatt JD, Podack ER.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.Semin Immunol 2010; 22:105-12; PMID:20226686; http://dx.doi.org/10.1016/j.smim.2010.02.001
24. Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.Crit Rev Immunol 2007; 27:451-62; PMID:18197807; http://dx.doi.org/10.1615/CritRevImmunol.v27.i5.40
25. Acres B, Limacher JM.MUC1 as a target antigen for cancer immunotherapy.Expert Rev Vaccines 2005; 4:493-502; PMID:16117706; http://dx.doi.org/10.1586/14760584.4.4.493
26. Rosenberg SA.Cancer vaccines based on the identification of genes encoding cancer regression antigens.Immunol Today 1997; 18:175-82; PMID:9136454; http://dx.doi.org/10.1016/S0167-5699(97)84664-6
27. Cavallo F, Calogero RA, Forni G.Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007; 7:707-13; PMID:17700704; http://dx.doi.org/10.1038/nrc2208
28. Beatty GL, Vonderheide RH.Telomerase as a universal tumor antigen for cancer vaccines.Expert Rev Vaccines 2008;7:881-7;PMID:18767939;http://dx.doi.org/10.1586/14760584.7.7.881
29. Andersen MH, Svane IM, Becker JC, Straten PT.The universal character of the tumor-associated antigen survivin.Clin Cancer Res 2007; 13:5991-4; PMID:17947459; http://dx.doi.org/10.1158/1078-0432.CCR-07-0686
30. Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA.Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays.Crit Rev Oncog 2008; 14:33-55; PMID:19105569; http://dx.doi.org/10.1615/CritRevOncog.v14.i1.30
31. ++ regulatory T cells enhances the antigenspecific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.Mol Ther 2005; 12:922-32; PMID:16257383; http://dx.doi.org/10.1016/j.ymthe.2005.02.029
32. Carvalho-Gaspar M, Jones ND, Luo S, Martin L, Brook MO, Wood KJ.Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells.J Immunol 2008; 180:6640-8; PMID:18453583
33. Sharma S, Dominguez AL, Manrique SZ, Cavallo F, Sakaguchi S, Lustgarten J.Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALBneuT tolerant mice.Cancer Res 2008; 68:7530-40; PMID:18794141; http://dx.doi.org/10.1158/0008-5472.CAN-08-1635
34. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TNM, Haanen JB, et al.Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.Cancer Res 2008; 68:8446-55; PMID:18922918; http://dx.doi.org/10.1158/0008-5472.CAN-08-1864
35. Pomié C, Ménager-Marcq I, van Meerwijk JPM.Murine CD8+ regulatory T lymphocytes: the new era.Hum Immunol 2008; 69:708-14; PMID:18817827; http://dx.doi.org/10.1016/j.humimm.2008.08.288
36. Joosten SA, Ottenhoff THM.Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination.Hum Immunol 2008; 69:760-70; PMID:18835413; http://dx.doi.org/10.1016/j.humimm.2008.07.017
37. Wang RF.CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.Hum Immunol 2008; 69:811-4; PMID:18817828; http://dx.doi.org/10.1016/j.humimm.2008.08.276
38. +(+) T cells induced by iris pigment epithelial cells display regulatory phenotype and acquire regulatory functions.Exp Eye Res 2007; 85:626-36; PMID:17720157; http://dx.doi.org/10.1016/j.exer.2007.07.015
39. Suzuki H, Shi Z, Okuno Y, Isobe KI.Are CD8+CD122+ cells regulatory T cells or memory T cells? Hum Immunol 2008; 69:751-4; PMID:18817826; http://dx.doi.org/10.1016/j.humimm.2008.08.285
40. Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, et al.CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.Eur J Immunol 2010;40:1375-85;PMID:20186876;http://dx.doi.org/10.1002/eji.200839210
41. Lu L, Cantor H.Generation and regulation of CD8(+) regulatory T cells.Cell Mol Immunol 2008; 5:401-6; PMID:19118505; http://dx.doi.org/10.1038/cmi.2008.50
42. Fenoglio D, Ferrera F, Fravega M, Balestra P, Battaglia F, Proietti M, et al.Advancements on phenotypic and functional characterization of non-antigen-specific CD8+CD28-regulatory T cells.Hum Immunol 2008; 69:745-50; PMID:18832002; http://dx.doi.org/10.1016/j.humimm.2008.08.282
43. Mocellin S, Marincola FM, Young HA.Interleukin-10 and the immune response against cancer: a counterpoint.J Leukoc Biol 2005; 78:1043-51; PMID:16204623; http://dx.doi.org/10.1189/jlb.0705358
44. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM.Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.Cancer Res 1997; 57:3325-30; PMID:9269988
45. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM.CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.J Immunol 1998; 160:870-6; PMID:9551923
46. Lewis JD, Shearer MH, Kennedy RC, Bright RK.Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.Cancer Res 2005; 65:2938-46; PMID:15805297; http://dx.doi.org/10.1158/0008-5472.CAN-04-2874
47. Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI.SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.Cancer Immunol Immunother 2002; 50:682-90; PMID:11862420; http://dx.doi.org/10.1007/s00262-001-0240-8